SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- CareFusion
(NYSE:CFN), a leading global medical technology company, and Terumo
Corporation, the largest medical technology company in Japan, today announced an exclusive,
eight-year agreement for CareFusion to co-brand, market and
distribute Terumo's SurFlash® line of safety peripheral
IV catheters for the acute care segment across the United States.
The agreement includes both SurFlash and SurFlash Plus Safety IV
Catheters, which are proven to improve the success of catheter
placement on the first attempt by an average of 20 percent. The
higher success rate for first placement can potentially enhance the
patient experience, reduce wasted catheters and save clinician
time, all of which reduce costs for the hospital.
"This agreement broadens our vascular access portfolio and adds
a critical link to enable CareFusion to provide an expanded range
of products," said Vivek Jain,
president of Procedural Solutions for CareFusion. "From skin
preparation to needle-free connectors and IV sets, the SurFlash
brand builds on our established leadership of clinically
differentiated products for vascular access procedures. We are
proud to collaborate with a global medical technology leader like
Terumo."
Terumo's agreement with CareFusion will focus solely on the U.S.
acute care hospital market.
"CareFusion's world-class clinical and commercial presence in
acute care infusion will accelerate the U.S. market impact of these
safety products faster than Terumo might otherwise
achieve," said Hideo Arase,
president and CEO of Terumo Medical Corporation and Terumo Americas
Holding, Inc. "The synergies are clear."
SurFlash and SurFlash Plus Safety IV Catheters have a passive
safety technology that completely encapsulates the needle reducing
the risk of needle stick injuries and exposure to blood borne
pathogens. The automatic engagement of this safety feature requires
no intentional effort from the clinician, allowing for minimal
technique change and faster adoption. These products are also
the only catheters with the double-flash SurFlash feature that
gives visual confirmation of when both the needle and catheter gain
entry into a vessel, minimizing the risk for failed attempts.
The SurFlash Plus Safety IV Catheter also incorporates a
proprietary blood control safety valve designed to minimize the
risk of blood exposure between the removal of the needle and the
attachment of the IV set. This helps create a cleaner access site
and IV hub area to reduce the risk of physical and visual exposure
to blood.
CareFusion will begin to market and distribute these products
this month. Financial terms of the agreement were not
disclosed.
About CareFusion Corporation
CareFusion (NYSE:
CFN) is a global corporation serving the health care industry with
products and services that help hospitals measurably improve the
safety and quality of care. The company develops industry-leading
technologies including Alaris® infusion pumps and IV
sets, MaxPlus® and MaxZero™ IV connectors and
sets, Pyxis® automated dispensing and patient
identification systems, AVEA®, LTV® series
and AirLife® ventilation and respiratory products,
ChloraPrep® products, MedMined® services for
data mining surveillance, V. Mueller® surgical
instruments, and an extensive line of products that support
interventional medicine. CareFusion employs approximately 15,000
people across its global operations. More information may be found
at www.carefusion.com.
About Terumo Medical Corporation
Founded in
1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation
(TMC) develops, manufactures, and markets high-quality medical
devices used in a broad range of applications in numerous
healthcare markets. TMC manufactures a broad portfolio of needles
and syringes, entry-site management products, and a line of sterile
connection devices used in hospitals and blood banks worldwide.
About Terumo
Corporation
Tokyo-based
Terumo Corporation is one of the world's leading medical device
manufacturers with $4.95 billion in
sales and operations in more than 160 nations. Founded in 1921, the
company develops, manufactures, and distributes world-class medical
devices including products for use in cardiothoracic surgery,
interventional procedures, and transfusion medicine; the company
also manufactures a broad array of syringe and hypodermic needle
products for hospital and physician office use. Terumo contributes
to society by providing valued products and services to the
healthcare market and by responding to the needs of healthcare
providers and the people they serve. Terumo Corporation's shares
are listed on the first section of the Tokyo Stock Exchange (No.
4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is
a component of the Nikkei 225, Japan's leading stock index.
(Logo:
http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)
SOURCE CareFusion Corporation